Back to top
more

Selecta Biosciences, Inc. (SELB)

(Delayed Data from NSDQ)

$2.35 USD

2.35
240,236

+0.23 (10.85%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

Selecta's (SELB) Q3 Loss Narrower-Than Expected, Revenues Beat

Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.

What's in Store for Selecta (SELB) This Earnings Season?

In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Lags Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences (SELB) Q2 Earnings & Sales Miss Estimates

Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.

What Awaits Selecta Biosciences (SELB) This Earnings Season?

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

Is Selecta Biosciences (SELB) Outperforming Other Medical Stocks This Year?

Is (SELB) Outperforming Other Medical Stocks This Year?

Selecta Biosciences (SELB) in Focus: Stock Moves 7.4% Higher

Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Is Selecta Biosciences (SELB) Stock Outpacing Its Medical Peers This Year?

Is (SELB) Outperforming Other Medical Stocks This Year?

Is Selecta (SELB) Stock a Solid Choice Right Now?

Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Selecta Biosciences Sees Hammer Chart Pattern: Time to Buy?

Selecta Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

Will Selecta Biosciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Selecta Biosciences.

Selecta Biosciences Enters Oversold Territory

Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher

Selecta Biosciences (SELB) moved big last session, as its shares jumped over 6% on the day.

    Selecta Biosciences (SELB) Enters Oversold Territory

    Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

      Selecta Biosciences (SELB): Strong Industry, Solid Earnings Estimate Revisions

      Selecta Biosciences (SELB) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.